Background: Levodopa-carbidopa intestinal gel (LCIG) is a continuously delivered Parkinson's disease therapy intended to stabilize plasma levodopa levels. Patients receiving LCIG require education and follow-up. Some LCIG support programs use video-assisted telenursing.
Objective: To examine how videoconferencing impacts satisfaction with LCIG support programs.
Methods: FACILITATE CARE (easibility of video-ssisted are for ntestinal evodopa nfusion with elenursing - observtional rial valuating patient and aregiver cceptance in al life) was a 12-week, prospective, open-label, 2-arm, parallel-group, observational study assessing satisfaction with LCIG support in patients who self-assigned to video or audio-only arms. Patients aged 18-85 years had completed LCIG titration and owned a videoconferencing device (video arm only). A visual analog scale measured satisfaction (1-10, 10 being most satisfied).
Results: Patients' mean (standard deviation) ages were 67.9 (7.4, = 26) and 71.1 (6.2, = 15) years in the video and audio arms, respectively. Patients, caregivers, and physicians in both groups reported satisfaction scores of 8-10 with LCIG support personnel, communication access, and assistance with becoming independent. At week 12, the Modified Caregiver Strain Index least square means change from baseline was lower in the video vs. audio arm (-2.3 [1.0] vs. 1.6 [1.2]). LCIG support personnel travel time was lower in the video vs. audio arm (125.7 [70.2] vs. 203.0 [70.0] minutes).
Conclusions: LCIG support programs are associated with high patient, caregiver, and physician satisfaction; video and audioconferencing satisfaction are similarly high. Video-assisted telenursing may be a convenient communication avenue and may reduce caregiver burden.
Registration: ClinicalTrials.gov; NCT04500106.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367587 | PMC |
| http://dx.doi.org/10.1177/20552076241271847 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Satisfaction with videoconferencing support for levodopa-carbidopa intestinal gel: An observational study.
Digit Health
August 2024
Division of Health Sciences, Department of Neurological and Psychiatric Nursing, Medical University of Gdansk, Gdansk, Poland.
Background: Levodopa-carbidopa intestinal gel (LCIG) is a continuously delivered Parkinson's disease therapy intended to stabilize plasma levodopa levels. Patients receiving LCIG require education and follow-up. Some LCIG support programs use video-assisted telenursing.
View Article and Find Full Text PDFLevodopa infusion therapies for Parkinson disease.
Curr Opin Neurol
August 2024
Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Purpose Of Review: to review recent progress in the development and use of continuous levodopa therapies in Parkinson disease (PD).
Recent Findings: Levodopa/Carbidopa intestinal gel (LCIG) is a continuous levodopa therapy which is widely used in the United States, Europe and other countries and is effective at reducing 'off' time. Recent work has shown that LCIG can be useful in managing dyskinesias and can improve nonmotor symptoms and quality of life.
Home-Based Titration with Duodenal Infusion of Levodopa-Carbidopa Intestinal Gel in People with Parkinson's Disease: An Observational Feasibility Study.
Parkinsons Dis
April 2024
Movement Disorder Clinic, Department of Neurology, Rigshospitalet, Copenhagen, Denmark.
Background: Testing and titration of the right levodopa equivalent dose are usually performed during a hospital admission. However, optimal dose titration in people with Parkinson's disease (PwPs) may depend on home environment, emotional stress, and physical activity of everyday life.
Objective: Firstly, to evaluate the feasibility and safety of a home-based LCIG titration program and patients'/caregivers' satisfaction.
Advanced therapies in Parkinson's disease: an individualized approach to their indication.
J Neural Transm (Vienna)
November 2024
Section of Movement Disorders and Neurostimulation, Department of Neurology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Article Synopsis
- - Device aided therapies (DAT) like LCIG, LECIG, CSAI, and DBS are used for Parkinson's disease when medications alone aren't enough, each with unique effectiveness, risks, and suitability.
- - These therapies should be evaluated individually as patients experience symptoms differently over time; one-size-fits-all approaches may not be effective.
- - The study emphasizes the need for ongoing assessments of patients to tailor DAT to their specific needs, enhancing both motor and non-motor symptom management.
Dyskinesia and Pain in Advanced Parkinson's Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study.
Neurol Ther
April 2024
AbbVie Inc., North Chicago, IL, USA.
Article Synopsis
- The DYSCOVER study compared levodopa-carbidopa intestinal gel (LCIG) to optimized medical treatment (OMT) in patients with Parkinson's disease and significant dyskinesia, finding that LCIG led to notable improvements in dyskinesia, pain, and health outcomes at 12 weeks.
- The analysis revealed moderate-to-strong positive correlations between dyskinesia severity and both pain and health-related quality of life scores, indicating that as one worsens, so does the other.
- Ultimately, the study suggests that addressing dyskinesia in these patients can positively impact their pain levels and overall quality of life.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!